专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

11. 发明申请

WO2010086259A1 PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS 审中-公开
标题翻译：作为NK3受体拮抗剂的哌啶衍生物
公开(公告)号：WO2010086259A1
公开(公告)日：2010-08-05
申请号：PCT/EP2010/050591
申请日：2010-01-19
申请人： F. HOFFMANN-LA ROCHE AG , KNUST, Henner , NETTEKOVEN, Matthias , RATNI, Hasane , RIEMER, Claus , VIFIAN, Walter
发明人： KNUST, Henner , NETTEKOVEN, Matthias , RATNI, Hasane , RIEMER, Claus , VIFIAN, Walter
IPC分类号： C07D401/12 , C07D401/14 , C07D413/14 , A61K31/454 , A61K31/4545 , A61P25/24 , A61P25/04 , A61P25/18 , A61P25/16 , A61P25/22
CPC分类号： C07D413/14 , C07D401/12 , C07D401/14
摘要： The present invention relates to a compounds of formula (I) wherein Ar 1 is aryl or a six membered heteroaryl; Ar 2 is aryl or a six membered heteroaryl; R 1 is hydrogen, halogen, lower alkyl, lower alkoxy or lower alkyl substituted by halogen; R 2 is hydrogen, halogen, lower alkyl, lower alkyl substituted by halogen or cyano; R 3 is hydrogen or lower alkyl; R 4 is hydrogen, lower alkyl, phenyl, optionally substituted by halogen, or is a five membered heteroaryl, optionally substituted by lower alkyl, or is aryl optionally substituted by halogen; is a six membered heterocyclic group, wherein X is -N(SO 2 CH 3 ); R 6 is hydrogen; Y is -N(R 7' )- R 7' is a 6-membered heteroaryl group, optionally substituted by cyano or C(O)-cycloalkyl, wherein the cycloalkyl group is optionally substituted by lower alkyl, n is 1; m is 1; o is1; p is 1; s is 0; t is 1; u is 1; or to a pharmaceutically active salt, a racemic mixture, an enantiomer, an optical isomer or a tautomeric form thereof. It has been found that the present compounds are high potential NK-3 receptor antagonist for the treatment of depression, pain, psychosis, Parkinson's disease, schizophrenia anxiety and attention deficit hyperactivity disorder (ADHD).
摘要翻译：本发明涉及式（I）的化合物，其中Ar 1是芳基或6元杂芳基; Ar 2是芳基或六元杂芳基; R1是氢，卤素，低级烷基，低级烷氧基或被卤素取代的低级烷基; R2是氢，卤素，低级烷基，被卤素或氰基取代的低级烷基; R3是氢或低级烷基; R4是氢，低级烷基，任选被卤素取代的苯基，或是任选被低级烷基取代的五元杂芳基，或者是被卤素任意取代的芳基; 是六元杂环基，其中X是-N（SO 2 CH 3）; R6是氢; Y是-N（R 7'）-R 7'是任选被氰基或C（O） - 环烷基取代的6元杂芳基，其中环烷基任选被低级烷基取代，n是1; m为1; o is1; p为1; s是0; t为1; 你是1 或其药物活性盐，外消旋混合物，对映体，旋光异构体或其互变异构形式。已经发现，本发明化合物是用于治疗抑郁症，疼痛，精神病，帕金森病，精神分裂症焦虑和注意缺陷多动障碍（ADHD）的高潜力NK-3受体拮抗剂。

12. 发明申请

WO2011073160A1 PYRROLIDINE DERIVATIVES AS NK - 3 RECEPTOR ANTAGONISTS 审中-公开
标题翻译：作为NK-3受体拮抗剂的吡咯烷衍生物
公开(公告)号：WO2011073160A1
公开(公告)日：2011-06-23
申请号：PCT/EP2010/069564
申请日：2010-12-14
申请人： F. HOFFMANN-LA ROCHE AG , KNUST, Henner , KOBLET, Andreas , NETTEKOVEN, Matthias , RATNI, Hasane , RIEMER, Claus , VIFIAN, Walter
发明人： KNUST, Henner , KOBLET, Andreas , NETTEKOVEN, Matthias , RATNI, Hasane , RIEMER, Claus , VIFIAN, Walter
IPC分类号： C07D401/06 , C07D401/14 , C07D403/14 , C07D405/14 , A61P25/28 , A61K31/44
CPC分类号： C07D401/14 , C07D207/14 , C07D401/06 , C07D405/14
摘要： The present application relates to compounds of formula (I) wherein R 1 is hydrogen, halogen, cyano, lower alkyl or lower alkyl substituted by halogen; n is 1, 2 or 3, if n is 2 or 3, R 1 can be different; R 2 is C 2-7 -alkyl or C 3-6 -cycloalkyl; R 3 is the group (II) wherein X is CH or N; R 5 is hydrogen, -C(O)-lower alkyl, -C(O)O-lower alkyl, S(O) 2 -lower alkyl, -C(O)CH 2 O-lower alkyl, -C(O)-CH 2 -CN, or is - or -C(O)-cycloalkyl, cycloalkyl, or -CH 2 -cycloalkyl, wherein the cycloalkyl groups are optionally substituted by lower alkyl, -CH 2 -O-Iower alkyl, lower alkoxy, CF 3 , halogen or cyano, or is -C(O)-heterocycloalkyl or heterocycloalkyl, or is -C(O)-heteroaryl or is heteroaryl or is -C(O)-aryl or aryl, which heterocycloalkyl, heteroaryl or aryl groups are optionally substituted by halogen, lower alkyl, =O, lower alkoxy, lower alkyl substituted by halogen, lower alkyl substituted by hydroxy, -C(O)-CH 2 -N(di-lower alkyl), C(O)NH-lower alkyl, C(O)NH 2 , -O-C(O)- lower alkyl, C(O)-lower alkyl, S(O) 2 -lower alkyl or cyano; R 4 is aryl, which is optionally substituted by halogen, hydroxy, lower alkyl, lower alkyl substituted by halogen, S(O) 2 -lower alkyl, cyano or by lower alkoxy; or to a pharmaceutically active salt thereof. It has been found that the present compounds are high potential NK-3 receptor antagonists for the treatment of depression, pain, psychosis, Parkinson's disease, schizophrenia, anxiety and attention deficit hyperactivity disorder (ADHD).
摘要翻译：本申请涉及其中R 1为氢，卤素，氰基，低级烷基或被卤素取代的低级烷基的式（I）化合物; n为1,2或3，如果n为2或3，则R1可以不同; R2是C2-7烷基或C3-6-环烷基; R3是其中X是CH或N的基团（II）; R5是氢，-C（O） - 低级烷基，-C（O）O-低级烷基，S（O）2-低级烷基，-C（O）CH2O-低级烷基，-C（O） CN，或是 - 或-C（O） - 环烷基，环烷基或-CH 2 - 环烷基，其中环烷基任选被低级烷基，-CH 2 -O-低级烷基，低级烷氧基，CF 3，卤素或氰基取代，或是-C（O） - 杂环烷基或杂环烷基，或是-C（O） - 杂芳基或是杂芳基或是-C（O） - 芳基或杂芳基，该杂环烷基，杂芳基或芳基任选被卤素取代，低级烷基，= O，低级烷氧基，被卤素取代的低级烷基，被羟基取代的低级烷基，-C（O）-CH 2 -N（二低级烷基），C（O）NH-低级烷基，C（O），-OC（O） - 低级烷基，C（O） - 低级烷基，S（O）2 - 低级烷基或氰基; R4是芳基，其任选被卤素，羟基，低级烷基，被卤素，S（O）2 - 低级烷基，氰基或低级烷氧基取代的低级烷基取代; 或其药物活性盐。已经发现，本发明化合物是用于治疗抑郁症，疼痛，精神病，帕金森病，精神分裂症，焦虑和注意缺陷多动障碍（ADHD）的高潜力NK-3受体拮抗剂。

13. 发明申请

WO2009019163A1 PYRROLIDINE ARYL-ETHER AS NK3 RECEPTOR ANTAGONISTS 审中-公开
标题翻译：吡咯烷酮ARYL-ETHER作为NK3受体拮抗剂
公开(公告)号：WO2009019163A1
公开(公告)日：2009-02-12
申请号：PCT/EP2008/059908
申请日：2008-07-29
申请人： F. HOFFMANN-LA ROCHE AG , JABLONSKI, Philippe , KAWASAKI, Kenichi , KNUST, Henner , LIMBERG, Anja , NETTEKOVEN, Matthias , RATNI, Hasane , RIEMER, Claus , WU, Xihan
发明人： JABLONSKI, Philippe , KAWASAKI, Kenichi , KNUST, Henner , LIMBERG, Anja , NETTEKOVEN, Matthias , RATNI, Hasane , RIEMER, Claus , WU, Xihan
IPC分类号： C07D401/08 , C07D401/06
CPC分类号： C07D401/06 , C07D401/08
摘要： The invention relates to a compound of general formula (I) wherein Ar 1 is aryl or a five or six membered heteroaryl; Ar 2 is aryl or a five or six membered heteroaryl; R 1 is hydrogen, halogen, lower alkyl, lower alkoxy, lower alkyl substituted by halogen, lower alkoxy substituted by halogen, S-lower alkyl, -S(O) 2 -lower alkyl, -S(O) 2 -di-lower alkyl amino, -(CH 2 ) q R, cyano, amino, mono or di-lower alkyl amino, NHC(O)-lower alkyl, cycloalkyl or is or a five membered heteroaryl, optionally substituted by lower alkyl; wherein R is cyano, di-lower alkyl amino or pyrrolidin-1-yl; R 2 is hydrogen, halogen, lower alkyl, lower alkyl substituted by halogen or cyano; R 3 is hydrogen or lower alkyl or CH 2 OH; R 4 is hydrogen, halogen, lower alkyl, lower alkyl substituted by halogen or cyano; n is 1, 2 or 3; in case n is 2 or 3, R 1 may be the same or different; o is 1, 2 or 3; in case o is 2 or 3, R 2 may be the same or different; p is 1, 2 or 3; in case p is 2 or 3, R 4 may be the same or different; q is 1 or 2; or to a pharmaceutically active salt thereof, including all stereoisomeric forms, individual diastereoisomers and enantiomers of the compound of formula (I) as well as racemic and non-racemic mixtures thereof. It has been found that the present compounds are high potential NK-3 receptor antagonists for the treatment of depression, pain, psychosis, Parkinson's disease, schizophrenia, anxiety and attention deficit hyperactivity disorder (ADHD).
摘要翻译：本发明涉及通式（I）的化合物，其中Ar 1是芳基或五或六元杂芳基; Ar 2是芳基或五或六元杂芳基; R 1是氢，卤素，低级烷基，低级烷氧基，被卤素取代的低级烷基，被卤素取代的低级烷氧基，S-低级烷基，-S（O）2 - 低级烷基，-S（O）氨基， - （CH 2）q R，氰基，氨基，一或二低级烷基氨基，NHC（O） - 低级烷基，环烷基或任选被低级烷基取代的五元杂芳基; 其中R是氰基，二低级烷基氨基或吡咯烷-1-基; R2是氢，卤素，低级烷基，被卤素或氰基取代的低级烷基; R3是氢或低级烷基或CH2OH; R4是氢，卤素，低级烷基，被卤素或氰基取代的低级烷基; n为1,2或3; 在n为2或3的情况下，R 1可以相同或不同; o是1,2或3; 在o为2或3的情况下，R 2可以相同或不同; p为1,2或3; 在p为2或3的情况下，R 4可以相同或不同; q为1或2; 或其药物活性盐，包括式（I）化合物的所有立体异构形式，单独的非对映异构体和对映异构体以及其外消旋和非外消旋混合物。已经发现，本发明化合物是用于治疗抑郁症，疼痛，精神病，帕金森病，精神分裂症，焦虑和注意缺陷多动障碍（ADHD）的高潜力NK-3受体拮抗剂。

14. 发明申请

WO2008148689A1 PROLINAMIDE DERIVATIVES AS NK3 ANTAGONISTS 审中-公开
标题翻译：丙酰胺衍生物作为NK3拮抗剂
公开(公告)号：WO2008148689A1
公开(公告)日：2008-12-11
申请号：PCT/EP2008/056589
申请日：2008-05-29
申请人： F. HOFFMANN-LA ROCHE AG , HAN, Bo , KNUST, Henner , NETTEKOVEN, Matthias , RATNI, Hasane , WU, Xihan
发明人： HAN, Bo , KNUST, Henner , NETTEKOVEN, Matthias , RATNI, Hasane , WU, Xihan
IPC分类号： C07D207/16 , C07D401/06 , C07D487/10 , A61P25/16 , A61P25/18 , A61K31/401
CPC分类号： C07D207/16 , C07D401/06 , C07D471/10
摘要： The present invention relates to a compound of formula (I) wherein R 1 is hydrogen, halogen, lower alkyl, lower alkyl substituted by halogen, lower alkoxy, or lower alkoxy substituted by halogen; R 2 is hydrogen or lower alkyl; R 3 , R 4 form together with the N-atom to which they are attached a non aromatic heterocyclic group, selected from R 5 is hydrogen or halogen; R 6 is phenyl, unsubstituted or substituted by cyano, halogen, lower alkyl, lower alkoxy, CF 3 , -(CH 2 ) 2 O-lower alkyl, C(O)-lower alkyl or C(O)O-lower alkyl, or is pyridinyl, unsubstituted or substituted by CF 3 , or is -C(O)-phenyl; R 7 is hydrogen or lower alkoxy; R 8 is phenyl, lower alkyl or -C(O)O-lower alkyl; R 9 is hydrogen or S(O) 2 -lower alkyl; R 10 is hydrogen or cycloalkyl; X is -CH 2 - or -C(O)-; p is 1 or 2; n is 1, 2 or 3; o is 1 or 2; or to a pharmaceutically suitable acid addition salt thereof which are high potential NK-3 receptor antagonists for the treatment of depression, pain, psychosis, Parkinson's disease, schizophrenia, anxiety and attention deficit hyperactivity disorder (ADHD).
摘要翻译：本发明涉及式（I）化合物，其中R 1为氢，卤素，低级烷基，被卤素取代的低级烷基，低级烷氧基或被卤素取代的低级烷氧基; R2是氢或低级烷基; R3，R4与它们所连接的N-原子一起形成非芳族杂环基，选自R5是氢或卤素; R 6为未取代或被氰基，卤素，低级烷基，低级烷氧基，CF 3， - （CH 2）2 O-低级烷基，C（O） - 低级烷基或C（O）O-低级烷基取代或被吡啶基取代的苯基，未取代或被CF 3取代，或为-C（O） - 苯基; R7是氢或低级烷氧基; R8是苯基，低级烷基或-C（O）O-低级烷基; R9是氢或S（O）2-低级烷基; R 10是氢或环烷基; X是-CH 2 - 或-C（O） - ; p为1或2; n为1,2或3; o是1或2; 或其药学上合适的酸加成盐，其是用于治疗抑郁症，疼痛，精神病，帕金森病，精神分裂症，焦虑和注意缺陷多动障碍（ADHD）的高潜力NK-3受体拮抗剂。

15. 发明申请

WO2007042420A1 ISOXAZOLE DERIVATIVES 审中-公开
标题翻译：异佛唑衍生物
公开(公告)号：WO2007042420A1
公开(公告)日：2007-04-19
申请号：PCT/EP2006/066959
申请日：2006-10-02
申请人： F. HOFFMANN-LA ROCHE AG , BUETTELMANN, Bernd , HAN, Bo , KNUST, Henner , NETTEKOVEN, Matthias , THOMAS, Andrew
发明人： BUETTELMANN, Bernd , HAN, Bo , KNUST, Henner , NETTEKOVEN, Matthias , THOMAS, Andrew
IPC分类号： C07D413/06 , C07D413/14 , A61K31/41 , A61P25/00
CPC分类号： C07D413/14
摘要： The present invention is concerned with aryl-isoxazole-4-carbonyl-indole-carboxylic acid amide derivatives of formula (I) wherein R 1 is hydrogen, lower alkyl or aryl; R 2 is lower alkyl; R 3 is hydrogen or halogen; R 4 /R 5 is independently from each other hydrogen, lower alkyl, lower alkinyl, -(CH 2 )n-cycloalkyl, -(CH 2 ) n -heteroaryl, -(CH 2 ) n -heterocyclyl or -(CH 2 ) n -OH; n is 0, 1, 2 or 3; and with their pharmaceutically acceptable acid addition salts. It has been found that this class of compounds show high affinity and selectivity for GABA α 5 receptor binding sites and might be useful as cognitive enhancer or for the treatment of cognitive disorders like Alzheimer's disease.
摘要翻译：本发明涉及式（I）的芳基 - 异恶唑-4-羰基 - 吲哚 - 羧酸酰胺衍生物，其中R 1是氢，低级烷基或芳基; R 2是低级烷基; R 3是氢或卤素; R 4和R 5彼此独立地为氢，低级烷基，低级炔基， - （CH 2 CH 2）n - 环烷基， - （（CH 2）n - 杂环基， - （CH 2）n - 杂环基或 - （CH 2）n - 2 ）_{名词 -OH; n为0,1,2或3; 和其药学上可接受的酸加成盐。已经发现，这类化合物显示出对GABA 5受体结合位点的高亲和力和选择性，并且可以用作认知增强剂或用于治疗诸如阿尔茨海默病的认知障碍。}

16. 发明申请

WO2011023626A1 PYRROLIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS 审中-公开
标题翻译：吡咯啉衍生物作为NK3受体拮抗剂
公开(公告)号：WO2011023626A1
公开(公告)日：2011-03-03
申请号：PCT/EP2010/062141
申请日：2010-08-20
申请人： F. HOFFMANN-LA ROCHE AG , JABLONSKI, Philippe , KNUST, Henner , NETTEKOVEN, Matthias , PATINY-ADAM, Angélique , RATNI, Hasane , RIEMER, Claus
发明人： JABLONSKI, Philippe , KNUST, Henner , NETTEKOVEN, Matthias , PATINY-ADAM, Angélique , RATNI, Hasane , RIEMER, Claus
IPC分类号： C07D401/14 , C07D413/14 , A61K31/4545 , A61K31/497 , A61K31/501 , A61K31/506 , A61P25/16 , A61P25/18 , A61P25/24 , A61P29/00
CPC分类号： C07D401/14 , C07D413/14
摘要： The present invention relates to a compounds of formula (I) wherein R 1 is hydrogen or lower alkyl; R 2 is hydrogen, lower alkyl, lower alkyl substituted by halogen or is halogen or CN, and may be independently from each other if o is 2; Ar 1 is aryl or heteroaryl; Ar 2 is aryl or heteroaryl; R'/R" are independently from each other hydrogen, lower alkyl, lower alkoxy, halogen, C(O)- lower alkyl, cyano or lower alkyl substituted by halogen; m is 0, 1, or 2 when n is 0; or m is 0 or 1 when n is 1; n is 0 or 1; o is 1 or 2; or to pharmaceutically active salts, racemic mixtures, enantiomers, optical isomers or to tautomeric forms thereof. It has been found that the present compounds are high potential NK-3 receptor antagonists for the treatment of depression, pain, psychosis, Parkinson's disease, schizophrenia, anxiety and attention deficit hyperactivity disorder (ADHD).
摘要翻译：本发明涉及式（I）化合物，其中R 1是氢或低级烷基; R 2是氢，低级烷基，被卤素取代的低级烷基，或者是卤素或CN，如果o是2，可以彼此独立地表示; Ar 1是芳基或杂芳基; Ar2是芳基或杂芳基; R'/ R“彼此独立地为氢，低级烷基，低级烷氧基，卤素，C（O） - 低级烷基，氰基或被卤素取代的低级烷基;当n为0时，m为0,1或2;或当n为1时，m为0或1; n为0或1; o为1或2;或者为药物活性盐，外消旋混合物，对映异构体，光学异构体或其互变异构形式。用于治疗抑郁症，疼痛，精神病，帕金森病，精神分裂症，焦虑和注意缺陷多动障碍（ADHD）的高潜在NK-3受体拮抗剂。

17. 发明申请

WO2009153179A1 PYRROLIDINE DERIVATIVES AS NK2 RECEPTOR ANTAGONISTS 审中-公开
标题翻译：吡咯啉衍生物作为NK2受体拮抗剂
公开(公告)号：WO2009153179A1
公开(公告)日：2009-12-23
申请号：PCT/EP2009/056987
申请日：2009-06-08
申请人： F. HOFFMANN-LA ROCHE AG , BISSANTZ, Caterina , JABLONSKI, Philippe , KNUST, Henner , KOBLET, Andreas , LIMBERG, Anja , NETTEKOVEN, Matthias , RATNI, Hasane , RIEMER, Claus
发明人： BISSANTZ, Caterina , JABLONSKI, Philippe , KNUST, Henner , KOBLET, Andreas , LIMBERG, Anja , NETTEKOVEN, Matthias , RATNI, Hasane , RIEMER, Claus
IPC分类号： C07D207/14 , C07D401/06 , C07D401/12 , C07D401/14 , C07D403/06 , C07D403/12 , C07D405/06 , C07D405/12 , C07D405/14 , C07D413/10 , A61K31/40 , A61K31/4439 , A61K31/443 , A61P25/24
CPC分类号： C07D207/14 , C07D401/06 , C07D401/12 , C07D401/14 , C07D403/06 , C07D403/12 , C07D405/06 , C07D405/12 , C07D405/14 , C07D413/10
摘要： The present invention relates to a compound of Formula (I) wherein R 1 is hydrogen, halogen, cyano or lower alkyl; n is 1, 2 or 3; R 2 is hydrogen or lower alkyl; R 3 is an aryl- or a heteroaryl ring, wherein the rings are optionally substituted by one or two substituents R'; R' is selected from hydrogen, halogen, lower alkyl, lower alkoxy, lower alkyl substituted by halogen, lower alkoxy substituted by halogen,-S(O) 2 -lower alkyl, CN, -NR 4 R 5 , -C(O)-lower alkyl, heterocyclyl or heteroaryl; R 4 /R 5 are independently from each other hydrogen, -(CO)CF 3 or lower alkyl or is a non aromatic heterocyclic group (II) wherein X is N or CH; Y is -CH(R 7 )-; -N(R 7' )-, or O or can be SO 2 ; R 6 is hydrogen, lower alkyl or hydroxy; R 7 is hydrogen, hydroxy, =0, lower alkyl, lower alkoxy, -S(O) 2 -lower alkyl, -C(O)-lower alkyl, -C(O)CH 2 O-lower alkyl, -CH 2 CN, -C(O)CH 2 CN, -C(O)-cycloalkyl wherein the cycloalkyl group is optionally substituted by cyano, lower alkyl, one or two halogen atoms, =0 or by amino, or is -C(O)O-lower alkyl, -NH-lower alkyl, -NRC(O)O-lower alkyl, -NRC(O)-lower alkyl or -CH 2 O-lower alkyl; and R 7' is hydrogen, lower alkyl, -(CH 2 ) q -S(O) 2 -lower alkyl, -(CH 2 ) q -S(O) 2 -cycloalkyl, -C(O)-lower alkyl, -(CH 2 ) q -cycloalkyl, -C(O)CH 2 -O-lower alkyl, -(CH 2 ) q CN, -C(O)CN, -C(O)CH 2 CN, lower alkyl substituted by halogen, lower alkenyl substituted by halogen, -C(O)-cycloalkyl wherein the cycloalkyl group is optionally substituted by cyano, lower alkyl, one or two halogen atoms, =0 or by amino, or is -C(O)O-lower alkyl or -(CH 2 )qO-lower alkyl and q is O - 3; or R 6 and R 7 may form together with the carbon atoms to which they are attach a five or six- membered non aromatic ring or R 6 and R 7 may form together with the nitrogen and carbon atoms to which they are attach a five or six-membered non aromatic ring; p is 0, 1 or 2; Ar is aryl- or heteroaryl, wherein the rings are optionally substituted by one or two substituents R"; R' ' is selected from hydrogen, halogen, lower alkyl, lower alkyl substituted by halogen, lower alkoxy, lower alkoxy substituted by halogen, -O-CH 2 -cycloalkyl, -NR 4 R 5 , -CN, -CH(CH 3 )CN, -CH 2 O-lower alkyl or pyrrolyl; m is 0, 1 or 2 and o is 0; o is 0, 1 or 2 and m is 1 or pharmaceutically active salts, racemic mixtures, enantiomers, optical isomers or tautomeric forms thereof. The compounds may be used for the treatment of depression, anxiety or schizophrenia.
摘要翻译：本发明涉及式（I）的化合物，其中R 1是氢，卤素，氰基或低级烷基; n为1,2或3; R2是氢或低级烷基; R3是芳基或杂芳基环，其中环任选地被一个或两个取代基R'取代; R'选自氢，卤素，低级烷基，低级烷氧基，被卤素取代的低级烷基，被卤素取代的低级烷氧基，-S（O）2 - 低级烷基，CN，-NR 4 R 5，-C（O） - 低级烷基，杂环基或杂芳基; R 4 / R 5彼此独立地为氢， - （CO）CF 3或低级烷基或为非芳族杂环基团（II），其中X为N或CH; Y是-CH（R 7） - ; -N（R 7'） - 或O或可以是SO 2; R6是氢，低级烷基或羟基; R 7是氢，羟基，= 0，低级烷基，低级烷氧基，-S（O）2 - 低级烷基，-C（O） - 低级烷基，-C（O）CH 2 O-低级烷基，-CH 2 CN，-C O）CH 2 CN，-C（O） - 环烷基，其中环烷基任选被氰基，低级烷基，一个或两个卤素原子取代，= 0或被氨基取代，或者是-C（O）O-低级烷基，-NH - 低级烷基，-NRC（O）O-低级烷基，-NRC（O） - 低级烷基或-CH 2 O-低级烷基; 并且R 7'是氢，低级烷基， - （CH 2）qS（O）2 - 低级烷基， - （CH 2）qS（O）2-环烷基，-C（O） - 低级烷基， - （CH 2），-C（O）CH 2 -O-低级烷基， - （CH 2）q CN，-C（O）CN，-C（O）CH 2 CN，被卤素取代的低级烷基，被卤素取代的低级链烯基，-C（O） - 环烷基，其中环烷基任选被氰基，低级烷基，一个或两个卤素原子，= O或氨基取代，或者是-C（O）O-低级烷基或 - （CH 2）q O-低级烷基，q是 O - 3; 或者R 6和R 7可以与它们所连接的五元或六元非芳香环的碳原子一起形成，或者R 6和R 7可以与它们所连接的五元或六元非芳环的氮和碳原子一起形成，芳香环 p为0,1或2; Ar是芳基或杂芳基，其中环任选地被一个或两个取代基R“取代; R”选自氢，卤素，低级烷基，被卤素取代的低级烷基，低级烷氧基，被卤素取代的低级烷氧基， O-CH 2 - 环烷基，-NR 4 R 5，-CN，-CH（CH 3）CN，-CH 2 O-低级烷基或吡咯基; m为0,1或2，o为0; o为0,1或2，m为1 或其药物活性盐，外消旋混合物，对映异构体，旋光异构体或互变异构体形式。化合物可用于治疗抑郁症，焦虑或精神分裂症。

18. 发明申请

WO2009033995A1 PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS 审中-公开
标题翻译：作为NK3受体拮抗剂的哌啶衍生物
公开(公告)号：WO2009033995A1
公开(公告)日：2009-03-19
申请号：PCT/EP2008/061649
申请日：2008-09-04
申请人： F. HOFFMANN-LA ROCHE AG , KNUST, Henner , NETTEKOVEN, Matthias , RATNI, Hasane , VIFIAN, Walter , WU, Xihan
发明人： KNUST, Henner , NETTEKOVEN, Matthias , RATNI, Hasane , VIFIAN, Walter , WU, Xihan
IPC分类号： C07D211/58 , C07D401/04 , A61K31/4468 , A61P25/18
CPC分类号： C07D211/58 , C07D401/04
摘要： The invention relates to a compound of general formula (I) wherein Ar 1 /Ar 2 are independently from each other phenyl or pyridinyl, which are optionally substituted by one or two substituents, selected from the group consisting of halogen, lower alkyl, lower alkoxy, lower alkyl substituted by halogen, lower alkoxy substituted by halogen, lower alkyl substituted by alkoxy, lower alkyl substituted by cyano, lower di-alkyl amino, pyridinyl or cyano; R 1 is hydrogen, lower alkyl, -(CH 2 ) 2 O-lower alkyl, or cycloalkyl: R 2 is -S(O) 2 -lower alkyl or -C(O) -lower alkyl; or R 1 and R 2 form together with the N-atom to which they are attached a pyrrolidin-2- one or a piperidin-2-one group; R 3 is hydrogen, halogen or lower alkyl; R 4 is hydrogen or lower alkyl; R 5 /R 5' are independently from each other hydrogen, lower alkyl, lower alkyl substituted by halogen, lower alkyl substituted by hydroxy or cycloalkyl; or R 5 and R 5' form together with the carbon-atom to which they are attached a cycloalkyl group; or to a pharmaceutically active salt thereof. It has been found that the present compounds are high potential NK-3 receptor antagonists for the treatment of depression, pain, psychosis, Parkinson's disease, schizophrenia, anxiety and attention deficit hyperactivity disorder (ADHD).
摘要翻译：本发明涉及通式（I）的化合物，其中Ar 1 / Ar 2彼此独立地为苯基或吡啶基，其任选被一个或两个选自以下的取代基取代：卤素，低级烷基，低级烷氧基，低级被卤素取代的烷基，被卤素取代的低级烷氧基，被烷氧基取代的低级烷基，被氰基取代的低级烷基，低级二烷基氨基，吡啶基或氰基; R 1是氢，低级烷基， - （CH 2）2 O-低级烷基或环烷基：R 2是-S（O）2 - 低级烷基或-C（O） - 低级烷基; 或R 1和R 2与它们所连接的N-原子一起形成吡咯烷-2-酮或哌啶-2-酮基; R3是氢，卤素或低级烷基; R4是氢或低级烷基; R5 / R5'彼此独立地为氢，低级烷基，被卤素取代的低级烷基，被羟基或环烷基取代的低级烷基; 或R 5和R 5'与它们所连接的碳原子一起形成环烷基; 或其药物活性盐。已经发现，本发明化合物是用于治疗抑郁症，疼痛，精神病，帕金森病，精神分裂症，焦虑和注意缺陷多动障碍（ADHD）的高潜力NK-3受体拮抗剂。

19. 发明申请

WO2011085886A1 PYRROLIDINE DERIVATIVES 审中-公开
标题翻译：吡咯烷衍生物
公开(公告)号：WO2011085886A1
公开(公告)日：2011-07-21
申请号：PCT/EP2010/069434
申请日：2010-12-13
申请人： F. HOFFMANN-LA ROCHE AG , KNUST, Henner , KOBLET, Andreas , NETTEKOVEN, Matthias , RATNI, Hasane , RIEMER, Claus , VIFIAN, Walter
发明人： KNUST, Henner , KOBLET, Andreas , NETTEKOVEN, Matthias , RATNI, Hasane , RIEMER, Claus , VIFIAN, Walter
IPC分类号： C07D207/14 , C07D401/06 , C07D403/06 , C07D405/06 , C07D407/04 , C07D413/06 , C07D417/14 , A61K31/5377 , A61P25/18
CPC分类号： A61K31/40 , A61K31/4025 , A61K31/454 , A61K31/4545 , A61K31/497 , A61K31/501 , A61K31/506 , A61K31/5377 , C07D207/14 , C07D401/06 , C07D403/06 , C07D405/06 , C07D407/04 , C07D413/06 , C07D417/14
摘要： The present invention relates to compounds of formula (I) or to a pharmaceutically active salt thereof. It has been found that the present compounds are high potential NK-3 receptor antagonists for the treatment of depression, pain, psychosis, Parkinson's disease, schizophrenia, anxiety and attention deficit hyperactivity disorder (ADHD).
摘要翻译：本发明涉及式（I）化合物或其药物活性盐。已经发现，本发明化合物是用于治疗抑郁症，疼痛，精神病，帕金森病，精神分裂症，焦虑和注意缺陷多动障碍（ADHD）的高潜力NK-3受体拮抗剂。

20. 发明申请

WO2010094667A1 PYRROLIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS 审中-公开
标题翻译：吡咯啉衍生物作为NK3受体拮抗剂
公开(公告)号：WO2010094667A1
公开(公告)日：2010-08-26
申请号：PCT/EP2010/051887
申请日：2010-02-16
申请人： F. HOFFMANN-LA ROCHE AG , KNUST, Henner , LIMBERG, Anja , NETTEKOVEN, Matthias , RATNI, Hasane , RIEMER, Claus
发明人： KNUST, Henner , LIMBERG, Anja , NETTEKOVEN, Matthias , RATNI, Hasane , RIEMER, Claus
IPC分类号： C07D207/08 , C07D401/12 , C07D401/14 , C07D403/14 , A61P25/00 , A61K31/496 , A61K31/506 , A61K31/4439 , A61K31/4545 , A61K31/501
CPC分类号： C07D207/08 , C07D207/09 , C07D401/06 , C07D401/12 , C07D401/14 , C07D403/12 , C07D403/14
摘要： The present invention relates to a compounds of formula I wherein A is -NR'-, -S-, -S(O)- or -S(O) 2 -; R' is hydrogen or lower alkyl; Ar is aryl or is a five or six membered heteroaryl group, containing one or two N-atoms; R is a five or six membered heterocyclic group X 1 is N or CH; and X 2 is -N(R 1 )-, -CH 2 -, -O-, -S-, -S(O)-, or -S(O) 2 -, R 1 is hydrogen, lower alkyl, S(O) 2 -lower alkyl, C(O)-lower alkyl, C(O)-cycloalkyl optionally substituted by lower alkyl; with the proviso that at least one of X 1 or X 2 contains a heteroatom, or is a five or six membered heteroaryl group, containing one or two N-atoms, which groups are unsubstituted or may be substituted by one or two R 1 ; wherein R 1 is lower alkyl or cyano; R 2 is lower alkyl substituted by halogen, halogen, cyano or nitro; R 3 is halogen; R 4 is hydrogen or lower alkyl; o is 1 or 2; in case o is 2, R 2 may be the same or different; p is 1 or 2; in case p is 2, R 3 may be the same or different; or to a pharmaceutically active salt thereof. It has been found that the present compounds are high potential NK-3 receptor antagonists for the treatment of depression, pain, psychosis, Parkinson's disease, schizophrenia, bipolar disorders, anxiety and attention deficit hyperactivity disorder (ADHD).
摘要翻译：本发明涉及式I化合物，其中A为-NR' - ， - S - ， - S（O） - 或-S（O）2 - ; R'是氢或低级烷基; Ar是芳基或是含有一个或两个N-原子的五或六元杂芳基; R是五或六元杂环基，X 1是N或CH; 并且X 2为-N（R 1） - ， - CH 2 - ， - O - ， - S - ， - S（O） - 或-S（O）2 - ，R 1为氢，低级烷基，S（O）低级烷基，C（O） - 低级烷基，任选被低级烷基取代的C（O） - 环烷基; 条件是X 1或X 2中的至少一个含有杂原子，或是含有一个或两个N原子的五或六元杂芳基，该基团是未取代的或可被一个或两个R 1取代; 其中R1是低级烷基或氰基; R2是被卤素，卤素，氰基或硝基取代的低级烷基; R3是卤素; R4是氢或低级烷基; o是1或2; 在o为2的情况下，R 2可以相同或不同; p为1或2; 在p为2的情况下，R 3可以相同或不同; 或其药物活性盐。已经发现，本发明化合物是用于治疗抑郁症，疼痛，精神病，帕金森病，精神分裂症，双相情感障碍，焦虑和注意缺陷多动障碍（ADHD）的高潜力NK-3受体拮抗剂。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式